Alloferon

Published · Researched 2026-09-21

Overview

Alloferons are antimicrobial/immunomodulatory peptides first isolated from the hemolymph of the firefly Calliphora vicina (alloferon 1: 12–13 aa; alloferon 2: a truncated form). The synthetic analog Allokin-alpha (alloferon-1 analog) is a registered drug in Russia since 2003 (Reg. #002829/01) — 1 mg lyophilizate ampoules for subcutaneous injection — used for HPV, herpes (HSV), hepatitis B/C, and erysipelas. It stimulates NK-cell cytotoxicity and interferon production. Alloferon is the only insect-derived peptide on this track with a registered antiviral drug product.

Social standing

  • Modest 2026 signal, Russia-adjacent. The clearest social artifact is an Aug 2026 Instagram image post (@/IG p/DboNdjKIQjg) presenting the "ÉLORIA ALLOKIN ALPHA" auto-injector pen as a "next-generation bioregulatory peptide (alloferon-1)" for immune response speed/accuracy — Russian-language caption, consumer-facing. Beyond this, alloferon mentions in the 2026 social corpus are sparse: no dedicated owner threads, no anecdote runs on Threads or Facebook Groups in this pass.
  • Retailer/educator layer: peptide-products.com (EU) sells ALLOKIN ALPHA 1 mg lyophilizate (€49.00, >97% purity, mannitol excipient, store ≤+5 °C); patent literature (EP 3583934 A1) documents the Russian registration and sequence.
  • Recurring praise (where mentioned): HPV/herpes antiviral story with a real drug registration — unusual among research peptides; insect-origin novelty.
  • Recurring complaints/failure modes: near-zero English-language community; auto-injector-style marketing posts read as vendor funnels; clinical trial visibility is low outside Russia.
  • Representative quotes: none with attributable peer-owner provenance.

Social validation

Tier 3 / UNVALIDATED — only one identifiable item-level social post (IG, Aug 2026) plus retailer listings and patent literature. No two independent social sources with discussion; cannot establish community standing. Included for research completeness.

Key specs table

Property Value
Identity (alloferon 1) His-Gly-Val-Ser-Gly-His-Gly-Gln-His-Gly-Val-His-Gly (13 aa; 12-aa form also reported)
Formula / MW C52H76N22O16 / 1265.3 Da
Origin Insect hemolymph (Calliphora vicina); synthetic analog = Allokin-alpha (Russia, 2003)
Mechanism (reported) Stimulates NK-cell cytotoxicity; induces IFN-α/γ; increases antiviral/antitumor resistance (murine/human in-vitro)
Forms Pharma: 1 mg lyophilizate ampoules (6 ampoules/box, "АЛЛОКИН-АЛЬФА") for SC injection; EU retail: 1 mg lyophilizate
Community-reported dosing None observed. Pharma: per Russian labeling/patent case reports, e.g. 1 mg SC every other day × 3 injections for genital herpes flare (individual case, NOT a community protocol)

Pricing

  • EU retail (observed 2026-09-20): peptide-products.com — ALLOKIN ALPHA 1 mg €49.00.
  • Russian pharmacy: registered drug; 2026 retail RUB price UNVERIFIED.
  • US gray market: no widely listed alloferon vials found (UNVERIFIED/unavailable).
  • Facebook Marketplace: no used listings observed — say so plainly (none found).

What's included / what's needed

Pharma: box of 6 ampoules (1 mg alloferon lyophilizate each), Russian insert; reconstitution with sterile saline/NaCl and SC syringes needed. EU retail: single 1 mg lyophilizate vial.

Support reality

Russian pharmacy distribution (Brand-Pharm); EU vendor (peptide-products.com) with standard shop support. No Western community infrastructure; dosing follows Russian labeling, not community protocols.

Community verdict

Alloferon's story is compelling on paper — insect immune peptide → registered antiviral drug — but in 2026 it exists in English-language social spaces as a curiosity, not a movement. The one consumer-facing post (ÉLORIA auto-injector framing) suggests someone is trying to build a Western brand around it, which bears watching; as of now there's no peer community to learn from.

Regulatory & safety status

Registered drug in Russia (Allokin-alpha, since 2003, for HPV/herpes/hepatitis) — NOT FDA-approved, no EMA approval. Outside Russia/CIS any Allokin-alpha/alloferon product is unapproved; EU retail listings are for research/collection with "not a traditional medicine" disclaimers. Safety signals (observed): Russian clinical use since 2003 with reported good tolerability; no Western safety database for gray-market product. Never imply US/EU human-use approval.

Image view breakdown

1/8 views obtained (JPEG, verified 2026-09-20):

  • hero: alloferon-hero.jpg (peptide-shop.com product photo — Russian "АЛЛОКИН-АЛЬФА" box + 6 ampoules) Missing views: side, rear, top, detail, inuse, scale, box — one real photo found; no second distinct angle available.

Not medical advice. This is a research summary of publicly discussed information, not a recommendation to use any substance.

Alloferon — hero view
hero view Original vendor page URL not recorded in research dossier

Named sources

  • ÉLORIA ALLOKIN ALPHA — Aug 2026 Instagram image post presenting alloferon-1 auto-injector pen (Aug 2026)

Source URLs were not recorded for these references.